Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.
Executive Summary
Barr's patent challenge against Pfizer's Estrostep Fe is the generic company's latest step in attempting to expand its oral contraceptives franchise.
You may also be interested in...
Allegra Growth Expected At 20% Annually; Generic Impact Possible In 2004
Aventis expects sales of its antihistamine Allegra (fexofenadine) to grow at a rate of about 20% annually, although generic competition could begin to have an impact beginning in 2004
Allegra Growth Expected At 20% Annually; Generic Impact Possible In 2004
Aventis expects sales of its antihistamine Allegra (fexofenadine) to grow at a rate of about 20% annually, although generic competition could begin to have an impact beginning in 2004
Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement